Results
Analysis of The imputation model implies a high number of missing eligible participants, with over 1,000 more individuals under the MAR imputed trial, and up to nearly 2,500 more under MNAR.When No estimate was found to be significant based on a 95% CI. Despite there being a clear change in the distribution of gestational age under MNAR conditions, and a large number of missing eligible, there is only weak evidence of selection bias in this study. This implies that gestational age only weakly modifies the effect of palivizumab on hospital admission.The implication is that receiving at least 1 dose of palivizumab appears to have little effect on hospital admission, and the results are robust to changes in the missing data assumption.